Polyrizon Ltd.’s Post

I'm pleased to share our latest article published in npj Antimicrobials and Resistance, titled "Narrative Review of Recent Developments and the Future of Penicillin Allergy De-labelling by Non-Allergists." This review explores the evolving landscape of penicillin allergy de-labelling (PADL) by non-allergists, covering recent advancements, ongoing debates, and future directions. We discuss new national guidelines, validated risk assessment tools, and the potential role of genetic and immunological tests in advancing PADL. 🔗 Read the full article here: https://lnkd.in/d2Xz85PC #Allergy #Immunology #Research #PADL #Penicillin #HealthcareInnovation #npjAntimicrobialsAndResistance

New study: BC Women's Hospital and Health Centre used Firstline to increase the "efficiency of penicillin allergy de-labeling": 🏷️ Identified 86.7% of patients as very low risk, closely matching PENFAST’s 88.4% and outperforming JAMA’s 60.2%. 🩺 The tool’s risk stratifications matched those of board-certified allergists. 💊 Enabled safe direct oral challenges streamlining the de-labeling process allowing non-allergists to safely de-label low-risk patients. Learn more: https://lnkd.in/gJBytp2d cc: Joanne Wang, Chelsea Elwood, Vanessa Paquette, Natasha Kwan, Stephanie Erdle, Melissa Watt, Julie van Schalkwyk, Jeffrey Bone, Ashley Roberts, Raymond Mak, Tiffany Wong, BC Children's Hospital, Vancouver, Provincial Health Services Authority.

🌟 New Phase 3 Study on Allergy Treatment Published 🌟 We are pleased to share the results of a Phase 3 clinical trial recently published in Allergy EAACI. The study evaluated a short-course subcutaneous immunotherapy for birch pollen-induced allergic rhinoconjunctivitis, using polymerized allergoids conjugated with #mannan. The findings demonstrate that this innovative approach significantly reduces allergy symptoms, decreases the need for medication, and improves patients' quality of life, all with a safe and well-tolerated treatment regimen requiring just five pre-seasonal doses. This research reinforces Inmunotek’s commitment to advancing allergen immunotherapy and providing effective, evidence-based solutions for allergy management. 🔗 Read the full study here: https://lnkd.in/dw8CaYwF #AllergyResearch #AllergenImmunotherapy

Assessing the strength of polyclonal allergen-specific serum antibodies has been made easier with this resource: https://buff.ly/3UVNZOL. This tool enables a quick evaluation of the avidity of these antibodies. Stay informed and updated on the latest developments in allergy research. #AllergyResearch #AvidityEvaluation

Aquestive Therapeutics positive topline results from a study evaluating Anaphylm™, a sublingual epinephrine film, as a potential alternative to traditional epinephrine delivery methods for managing Oral Allergy Syndrome. Learn more: https://lnkd.in/ejNR9-45

Attention allergy sufferers! A recent study has shown that allergen immunotherapy (AIT), also known as allergy shots, is the only causal treatment for respiratory allergies. The long-term real-life effectiveness of AIT has now been demonstrated beyond just randomized controlled trials. This retrospective cohort study using claims data between 2007 and 2017 showed that AIT-treated subjects consistently had greater reductions in allergic rhinitis and asthma prescriptions compared to control subjects, including both asthma controller and reliever prescriptions. Additionally, the AIT group had a significantly greater likelihood of stepping down asthma treatment and experiencing fewer severe asthma exacerbations. Say goodbye to allergies with the sustained effectiveness of allergy shots! #allergyshots #immunotherapy #healthyliving Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study. Fritzsching, Benedikt et al. The Lancet Regional Health – Europe, Volume 13, 100275

I am excited to share our latest research article in Clinical Medicine, titled "The appropriateness of penicillin allergy de-labelling by non-allergist clinical ward teams." This study is a significant step forward in understanding and improving the management of penicillin allergies in clinical settings. Thank you to our lead author, Neil Powell, and co-authors Daniel Hearsey, Michael Wilcock, and Jonathan Sandoe for their incredible collaboration and dedication to this project. Your expertise and hard work made this possible. You can read the full article here:  https://lnkd.in/dAR9wCzP #MedicalResearch #Allergy #Immunology #PenicillinAllergy #ClinicalCare

Insights into Oral Immunotherapy: Enhancing Treatment for Milk Allergies. Discover more at https://buff.ly/4bN3Chi. Stay informed on the latest advancements in allergy treatment. #AllergyTreatment #Immunotherapy

Join the Iowa HHS Healthcare Associated Infections (HAI) Program on Tuesday, May 20, 2024, at 12:00 p.m. for a FREE webinar.   This course discusses the critical issue of patient mislabeling regarding penicillin allergy, a problem with significant implications for both healthcare providers and patients. Participants will gain the knowledge and skills necessary to address and mitigate the consequences of inaccurate penicillin allergy reporting. By the end of this course, participants will emerge with a heightened understanding of the complexities surrounding penicillin allergy mislabeling and the strategies necessary to ensure safe and effective antibiotic treatment for all patients.   At the conclusion of this webinar, the participants should be better able to: · Discuss penicillin allergy mislabeling in patients that present to the dental clinic. · Identify potential consequences of antibiotic treatment in a patient who reports penicillin allergy. · Review resources and tools for identifying and facilitating a penicillin allergy reassessment. This accredited continuing education activity is designed for dentists and allied dental professionals. Register in advance here: https://lnkd.in/g5i53Zfh

Multiplex assays play a crucial role in allergy diagnosis. A comparison between Allergy Explorer 2 and ImmunoCAP ISAC E112i showcases advancements in this field. Stay informed about the latest developments in allergy testing. #AllergyTesting #MedicalInnovation